





## Characterization of PLN-R14Del mutation in human induced pluripotent stem cell-derived cardiomyocytes

Badone B.1\*, Ronchi C.1, Rutigliano V.1, Zaza A.1

\*(Beatrice Badone) b.badone@campus.unimib.it

<sup>1</sup> Department of Biotechnology and Bioscience, University of Milano-Bicocca, Milan, Italy

Keywords: Phospholamban mutation, R14Del mutation, PLN/SERCA2a interaction, hiPSC-CMs, cardiac ECC.

**Background:** Phospholamban (PLN) is the natural inhibitor of the sarco/endoplasmic reticulum Ca<sup>2+</sup> ATPase (SERCA2a) in cardiac cells. Their interaction, and its regulation, is crucial for the excitation-contraction coupling (ECC) in cardiomyocytes. The R14Del mutation is characterized by a deletion of Arg-14 of PLN and it is associated with a severe phenotype of arrhythmogenic and dilated cardiomyopathy. The mutation has been already studied in several models, such as HEK293, mice, and human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). Here we wanted to: 1) test how PLN-R14Del (MUT) hiPSC-CMs and their isogenic controls (WT) cultured in a standard monolayer (ML) format differ in terms of Ca<sup>2+</sup> dynamics; 2) test in both groups a pure SERCA2a activator DRUG A, which prevents the interaction PLN/SERCA2a.

**Methods:** both WT and MUT hiPSC-CMs were thawed and plated in single glass petri dishes, to allow simultaneous electrophysiological recordings and  $Ca^{2+}$  measurements.  $Ca^{2+}$ -transient recordings were performed in field stimulation at 1 Hz (or increasing frequencies). All experiments were performed under Tyrode's (TYR) superfusion.

**Results:** V-induced Ca<sup>2+</sup>-transients did not differ between WT and MUT MLs; the sarcoplasmic reticulum (SR) Ca<sup>2+</sup>-content, was not significantly different between groups although it tended to be higher in MUT MLs. The half time of Ca<sup>2+</sup>-transient decay ( $t_{1/2}$ ) was significantly faster (small  $t_{1/2}$ ) in MUT MLs than the WT ones (p<0.05). The pure SERCA2a stimulator DRUG A (1 µM) significantly accelerates the decay in both WT (p<0.0001) and MUT MLs (p<0.01). Data obtained from the staircase protocol (application of four increasing frequencies) for diastolic Ca<sup>2+</sup>, showed a flat staircase in MUT MLs and a steeply positive one (implying accumulation of Ca<sup>2+</sup> in the cytosol) in WT MLs (p<0.05 vs MUT). DRUG A 1 µM significantly reduced the accumulation of diastolic Ca<sup>2+</sup> in WT (p<0.01), whereas it was similar to basal conditions in MUT MLs. **Conclusions:** these results suggest that the PLN-R14Del mutation leads to a PLN loss-of-function for the following reasons: 1) the faster decay (small  $t_{1/2}$ ) in MUT compared to WT MLs; 2) the lack of effect of DRUG A during the staircase protocol in MUT MLs. In particular, the latter indicates that in MUT MLs SERCA2a function is enhanced.

